Login to Your Account



Pharma: Other News To Note


Wednesday, July 18, 2012
• Janssen Biotech Inc., of Horsham, Pa., a unit of Johnson & Johnson, said it submitted a supplemental biologics license application to the FDA and a Type II Variation to the European Medicines Agency requesting approval of Simponi (golimumab) in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription